PME Breakfast Symposium (Non-CME)
Thursday, October 23 | 7:00 AM - 8:00 AM
A Triad of Diseases: A Treatment Strategy for Patients With T2D, CVD, and CKD
Davida F. Kruger, MSN, APN-BC,BC-ADM
Sponsored by Novo Nordisk.
Program Description:
PME Lunch Symposium (Non-CME)
Thursday, October 23 | 11:30 AM – 12:30 PM
Aldosterone as an underlying driver of hypertension and CV and kidney
Surendra Sivarajah, MD; Justin Fongemie, PharmD, BCCP
Sponsored by AstraZeneca.
Program Description:
Information is coming soon.
PME Dinner Symposium (Non-CME)
Thursday, October 23 | 6:15 PM - 7:15 PM
Tirzepatide: A Dual GIP and GLP-1 Receptor Agonist
Rajveer Sachdev, MD, MBA
Sponsored by Lilly.
Program Description:
Learn about tirzepatide, a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, the active ingredient in Zepbound® (tirzepatide) and Mounjaro® (tirzepatide). In this program, we will review clinical efficacy, safety, and dosing and administration information about Zepbound and Mounjaro.
Attendees will have the opportunity to ask questions to the speaker at the conclusion of the program.
PME Breakfast Symposium (Non-CME)
Friday, October 24 | 6:45 AM – 7:45 AM
Cracking the Code: Uncover a Hidden Driver of Resistant Hypertension
Honey East, MD, FACP; John W. Ostrominski, MD; Jorge Plutzky, MD, FACC, FNLA
Sponsored by Corcept Therapeutics.
Program Description:
Join us as leading experts uncover the role of hypercortisolism as a hidden driver of resistant hypertension and share their clinical insights to help identify this often-overlooked contributor.
PME Lunch Symposium (Non-CME)
Friday, October 24 | 12:30 PM – 1:30 PM
Advances in MASH: Data From a Phase 3 Study
Amreen Dinani, MD, FRCPC, ABOM
Sponsored by Novo Nordisk.
Program Description:
Join us as we discuss the importance of early identification of MASH (metabolic dysfunction-associated steatohepatitis), including how to accurately identify and select patients who are at risk for clinically significant fibrosis. We will also discuss clinical trial data for patients with MASH and stage 2 or 3 fibrosis.
PME Dinner Symposium (Non-CME)
Friday, October 24 | 6:30 PM - 7:30 PM
Evidence-Based Treatment of Recurrent Pericarditis
John Ryan, MD
Sponsored by Kiniksa Pharmaceuticals.
Program Description:
For many patients, single- or first-episode pericarditis is just the beginning of their journey. Up to 30% of patients with pericarditis will experience a recurrent episode within 18 months, despite treatment with traditional therapies. Managing recurrent pericarditis (RP) can be a challenge for clinicians because pericarditis and RP are distinctly different in pathology, duration of disease, and risk of both recurrence and complications. At this Industry Expert Theater, we will review the diagnosis of RP, the underlying interleukin-1 (IL-1) pathway that drives the repetitive cycle of recurrence, insights regarding RP disease duration, and a treatment option for RP.
PME Breakfast Symposium (Non-CME)
Saturday, October 25 | 7:00 AM – 8:00 AM
Severe Hypertriglyceridemia and FCS: Navigating Guidelines, Gaps, and Progress
Christie M. Ballantyne, MD, FNLA
Sponsored by Arrowhead Pharmaceuticals.
Program Description:
Information is coming soon.